Review



recombinant stat1 proteins  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    MedChemExpress recombinant stat1 proteins
    Recombinant Stat1 Proteins, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+stat1+proteins/pm41763198-307-0-6?v=MedChemExpress
    Average 94 stars, based on 1 article reviews
    recombinant stat1 proteins - by Bioz Stars, 2026-07
    94/100 stars

    Images



    Similar Products

    94
    MedChemExpress recombinant stat1 proteins
    Recombinant Stat1 Proteins, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+stat1+proteins/pm41763198-307-0-6?v=MedChemExpress
    Average 94 stars, based on 1 article reviews
    recombinant stat1 proteins - by Bioz Stars, 2026-07
    94/100 stars
      Buy from Supplier

    93
    TargetMol stat1
    Figure 3 Orlistat suppressed PD-L1 via inhibition of FOXM1 signaling. (A) Volcano plot of the expression of the reported transcription factors that regulated the expression of PD-L1. These TFs include <t>STAT1,</t> ATF3, IRF2, TFEB, IRF1, YY1, STAT3, JUN, HSF1, NFκB, SP1, FOXP3, BRD4, EZH2, MYC, HIF-1α, and FOXM1. (B, C) qRT-PCR measurement of mRNA expression of FOXM1 after orlistat (40 µM) treatment for 0 hour, 24 hours, or 48 hours in AGS and HCT116 (B), MC38 and CT26 cells (C). (D) WB analysis of FOXM1 protein levels after orlistat treatment for different times (0 hour, 24 hours, 48 hours) in AGS, HCT116, MC38, and CT26 cells. (E) Representative images of immunohistochemical staining of FOXM1 protein expression in resected tumors at day 25. Scale bar=50 µm. (F) The expression of PD-L1 mRNA in AGS and MC38 cells after transfection with FOXM1 overexpression or knockdown. (G) WB for PD-L1 protein levels after FOXM1 overexpression or knockdown in AGS and MC38 cells. (H) Schematic representation of the PD-L1 gene promoter regions and primer pairs used for ChIP assays. (I) ChIP-qPCR assay was used to detect the binding of FOXM1 to the PD-L1 promoter at the (+222 to +450 bp) region in AGS cells. (J) ChIP-qPCR analysis of the impact of orlistat (40 µM) on the binding of FOXM1 to the PD-L1 promoter. (K) The luciferase activity of PD-L1 promoter after FOXM1 overexpression with or without orlistat (40 µM). HEK293T cells in 24-well plates were transfected with FOXM1 plasmids or control. The luciferase activity was measured 36 hours later. *p<0.05, **p<0.01, ***p<0.001.
    Stat1, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+stat1+proteins/pm40139835-65-2-3?v=TargetMol
    Average 93 stars, based on 1 article reviews
    stat1 - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    94
    MedChemExpress d8375 recombinant stat1 protein mce hy p73628
    Figure 3 Orlistat suppressed PD-L1 via inhibition of FOXM1 signaling. (A) Volcano plot of the expression of the reported transcription factors that regulated the expression of PD-L1. These TFs include <t>STAT1,</t> ATF3, IRF2, TFEB, IRF1, YY1, STAT3, JUN, HSF1, NFκB, SP1, FOXP3, BRD4, EZH2, MYC, HIF-1α, and FOXM1. (B, C) qRT-PCR measurement of mRNA expression of FOXM1 after orlistat (40 µM) treatment for 0 hour, 24 hours, or 48 hours in AGS and HCT116 (B), MC38 and CT26 cells (C). (D) WB analysis of FOXM1 protein levels after orlistat treatment for different times (0 hour, 24 hours, 48 hours) in AGS, HCT116, MC38, and CT26 cells. (E) Representative images of immunohistochemical staining of FOXM1 protein expression in resected tumors at day 25. Scale bar=50 µm. (F) The expression of PD-L1 mRNA in AGS and MC38 cells after transfection with FOXM1 overexpression or knockdown. (G) WB for PD-L1 protein levels after FOXM1 overexpression or knockdown in AGS and MC38 cells. (H) Schematic representation of the PD-L1 gene promoter regions and primer pairs used for ChIP assays. (I) ChIP-qPCR assay was used to detect the binding of FOXM1 to the PD-L1 promoter at the (+222 to +450 bp) region in AGS cells. (J) ChIP-qPCR analysis of the impact of orlistat (40 µM) on the binding of FOXM1 to the PD-L1 promoter. (K) The luciferase activity of PD-L1 promoter after FOXM1 overexpression with or without orlistat (40 µM). HEK293T cells in 24-well plates were transfected with FOXM1 plasmids or control. The luciferase activity was measured 36 hours later. *p<0.05, **p<0.01, ***p<0.001.
    D8375 Recombinant Stat1 Protein Mce Hy P73628, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+stat1+proteins/pm41763198-212-238-242?v=MedChemExpress
    Average 94 stars, based on 1 article reviews
    d8375 recombinant stat1 protein mce hy p73628 - by Bioz Stars, 2026-07
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress gst stat1 recombinant proteins
    Figure 3 Orlistat suppressed PD-L1 via inhibition of FOXM1 signaling. (A) Volcano plot of the expression of the reported transcription factors that regulated the expression of PD-L1. These TFs include <t>STAT1,</t> ATF3, IRF2, TFEB, IRF1, YY1, STAT3, JUN, HSF1, NFκB, SP1, FOXP3, BRD4, EZH2, MYC, HIF-1α, and FOXM1. (B, C) qRT-PCR measurement of mRNA expression of FOXM1 after orlistat (40 µM) treatment for 0 hour, 24 hours, or 48 hours in AGS and HCT116 (B), MC38 and CT26 cells (C). (D) WB analysis of FOXM1 protein levels after orlistat treatment for different times (0 hour, 24 hours, 48 hours) in AGS, HCT116, MC38, and CT26 cells. (E) Representative images of immunohistochemical staining of FOXM1 protein expression in resected tumors at day 25. Scale bar=50 µm. (F) The expression of PD-L1 mRNA in AGS and MC38 cells after transfection with FOXM1 overexpression or knockdown. (G) WB for PD-L1 protein levels after FOXM1 overexpression or knockdown in AGS and MC38 cells. (H) Schematic representation of the PD-L1 gene promoter regions and primer pairs used for ChIP assays. (I) ChIP-qPCR assay was used to detect the binding of FOXM1 to the PD-L1 promoter at the (+222 to +450 bp) region in AGS cells. (J) ChIP-qPCR analysis of the impact of orlistat (40 µM) on the binding of FOXM1 to the PD-L1 promoter. (K) The luciferase activity of PD-L1 promoter after FOXM1 overexpression with or without orlistat (40 µM). HEK293T cells in 24-well plates were transfected with FOXM1 plasmids or control. The luciferase activity was measured 36 hours later. *p<0.05, **p<0.01, ***p<0.001.
    Gst Stat1 Recombinant Proteins, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+stat1+proteins/pm40195316-357-0-3?v=MedChemExpress
    Average 94 stars, based on 1 article reviews
    gst stat1 recombinant proteins - by Bioz Stars, 2026-07
    94/100 stars
      Buy from Supplier

    90
    Abnova recombinant stat1 protein h00006772
    Figure 3 Orlistat suppressed PD-L1 via inhibition of FOXM1 signaling. (A) Volcano plot of the expression of the reported transcription factors that regulated the expression of PD-L1. These TFs include <t>STAT1,</t> ATF3, IRF2, TFEB, IRF1, YY1, STAT3, JUN, HSF1, NFκB, SP1, FOXP3, BRD4, EZH2, MYC, HIF-1α, and FOXM1. (B, C) qRT-PCR measurement of mRNA expression of FOXM1 after orlistat (40 µM) treatment for 0 hour, 24 hours, or 48 hours in AGS and HCT116 (B), MC38 and CT26 cells (C). (D) WB analysis of FOXM1 protein levels after orlistat treatment for different times (0 hour, 24 hours, 48 hours) in AGS, HCT116, MC38, and CT26 cells. (E) Representative images of immunohistochemical staining of FOXM1 protein expression in resected tumors at day 25. Scale bar=50 µm. (F) The expression of PD-L1 mRNA in AGS and MC38 cells after transfection with FOXM1 overexpression or knockdown. (G) WB for PD-L1 protein levels after FOXM1 overexpression or knockdown in AGS and MC38 cells. (H) Schematic representation of the PD-L1 gene promoter regions and primer pairs used for ChIP assays. (I) ChIP-qPCR assay was used to detect the binding of FOXM1 to the PD-L1 promoter at the (+222 to +450 bp) region in AGS cells. (J) ChIP-qPCR analysis of the impact of orlistat (40 µM) on the binding of FOXM1 to the PD-L1 promoter. (K) The luciferase activity of PD-L1 promoter after FOXM1 overexpression with or without orlistat (40 µM). HEK293T cells in 24-well plates were transfected with FOXM1 plasmids or control. The luciferase activity was measured 36 hours later. *p<0.05, **p<0.01, ***p<0.001.
    Recombinant Stat1 Protein H00006772, supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+stat1+proteins/pm39919329-116-1-4?v=Abnova
    Average 90 stars, based on 1 article reviews
    recombinant stat1 protein h00006772 - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    95
    Boster Bio stat1
    Figure 3 Orlistat suppressed PD-L1 via inhibition of FOXM1 signaling. (A) Volcano plot of the expression of the reported transcription factors that regulated the expression of PD-L1. These TFs include <t>STAT1,</t> ATF3, IRF2, TFEB, IRF1, YY1, STAT3, JUN, HSF1, NFκB, SP1, FOXP3, BRD4, EZH2, MYC, HIF-1α, and FOXM1. (B, C) qRT-PCR measurement of mRNA expression of FOXM1 after orlistat (40 µM) treatment for 0 hour, 24 hours, or 48 hours in AGS and HCT116 (B), MC38 and CT26 cells (C). (D) WB analysis of FOXM1 protein levels after orlistat treatment for different times (0 hour, 24 hours, 48 hours) in AGS, HCT116, MC38, and CT26 cells. (E) Representative images of immunohistochemical staining of FOXM1 protein expression in resected tumors at day 25. Scale bar=50 µm. (F) The expression of PD-L1 mRNA in AGS and MC38 cells after transfection with FOXM1 overexpression or knockdown. (G) WB for PD-L1 protein levels after FOXM1 overexpression or knockdown in AGS and MC38 cells. (H) Schematic representation of the PD-L1 gene promoter regions and primer pairs used for ChIP assays. (I) ChIP-qPCR assay was used to detect the binding of FOXM1 to the PD-L1 promoter at the (+222 to +450 bp) region in AGS cells. (J) ChIP-qPCR analysis of the impact of orlistat (40 µM) on the binding of FOXM1 to the PD-L1 promoter. (K) The luciferase activity of PD-L1 promoter after FOXM1 overexpression with or without orlistat (40 µM). HEK293T cells in 24-well plates were transfected with FOXM1 plasmids or control. The luciferase activity was measured 36 hours later. *p<0.05, **p<0.01, ***p<0.001.
    Stat1, supplied by Boster Bio, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+stat1+proteins/ppr0962075-47-14-16?v=Boster+Bio
    Average 95 stars, based on 1 article reviews
    stat1 - by Bioz Stars, 2026-07
    95/100 stars
      Buy from Supplier

    95
    Boster Bio p stat1
    Molecular docking and dynamic simulations of ROF and JAKs/STATs signaling molecules (A) The binding modes of ROF toward JAK2, JAK3, <t>STAT1,</t> and STAT3. (B–F) The dynamic simulations of JAK2-ROF and JAK3-ROF complexes. The HBond (B), RMSD curves (C), RMSF values (D), Rg values (E), and SASA (F) were analyzed by GROMACS.
    P Stat1, supplied by Boster Bio, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+stat1+proteins/pmc11500133-174-13-28?v=Boster+Bio
    Average 95 stars, based on 1 article reviews
    p stat1 - by Bioz Stars, 2026-07
    95/100 stars
      Buy from Supplier

    Image Search Results


    Figure 3 Orlistat suppressed PD-L1 via inhibition of FOXM1 signaling. (A) Volcano plot of the expression of the reported transcription factors that regulated the expression of PD-L1. These TFs include STAT1, ATF3, IRF2, TFEB, IRF1, YY1, STAT3, JUN, HSF1, NFκB, SP1, FOXP3, BRD4, EZH2, MYC, HIF-1α, and FOXM1. (B, C) qRT-PCR measurement of mRNA expression of FOXM1 after orlistat (40 µM) treatment for 0 hour, 24 hours, or 48 hours in AGS and HCT116 (B), MC38 and CT26 cells (C). (D) WB analysis of FOXM1 protein levels after orlistat treatment for different times (0 hour, 24 hours, 48 hours) in AGS, HCT116, MC38, and CT26 cells. (E) Representative images of immunohistochemical staining of FOXM1 protein expression in resected tumors at day 25. Scale bar=50 µm. (F) The expression of PD-L1 mRNA in AGS and MC38 cells after transfection with FOXM1 overexpression or knockdown. (G) WB for PD-L1 protein levels after FOXM1 overexpression or knockdown in AGS and MC38 cells. (H) Schematic representation of the PD-L1 gene promoter regions and primer pairs used for ChIP assays. (I) ChIP-qPCR assay was used to detect the binding of FOXM1 to the PD-L1 promoter at the (+222 to +450 bp) region in AGS cells. (J) ChIP-qPCR analysis of the impact of orlistat (40 µM) on the binding of FOXM1 to the PD-L1 promoter. (K) The luciferase activity of PD-L1 promoter after FOXM1 overexpression with or without orlistat (40 µM). HEK293T cells in 24-well plates were transfected with FOXM1 plasmids or control. The luciferase activity was measured 36 hours later. *p<0.05, **p<0.01, ***p<0.001.

    Journal: Journal for immunotherapy of cancer

    Article Title: Orlistat facilitates immunotherapy via AKT-FOXO3a-FOXM1-mediated PD-L1 suppression.

    doi: 10.1136/jitc-2024-008923

    Figure Lengend Snippet: Figure 3 Orlistat suppressed PD-L1 via inhibition of FOXM1 signaling. (A) Volcano plot of the expression of the reported transcription factors that regulated the expression of PD-L1. These TFs include STAT1, ATF3, IRF2, TFEB, IRF1, YY1, STAT3, JUN, HSF1, NFκB, SP1, FOXP3, BRD4, EZH2, MYC, HIF-1α, and FOXM1. (B, C) qRT-PCR measurement of mRNA expression of FOXM1 after orlistat (40 µM) treatment for 0 hour, 24 hours, or 48 hours in AGS and HCT116 (B), MC38 and CT26 cells (C). (D) WB analysis of FOXM1 protein levels after orlistat treatment for different times (0 hour, 24 hours, 48 hours) in AGS, HCT116, MC38, and CT26 cells. (E) Representative images of immunohistochemical staining of FOXM1 protein expression in resected tumors at day 25. Scale bar=50 µm. (F) The expression of PD-L1 mRNA in AGS and MC38 cells after transfection with FOXM1 overexpression or knockdown. (G) WB for PD-L1 protein levels after FOXM1 overexpression or knockdown in AGS and MC38 cells. (H) Schematic representation of the PD-L1 gene promoter regions and primer pairs used for ChIP assays. (I) ChIP-qPCR assay was used to detect the binding of FOXM1 to the PD-L1 promoter at the (+222 to +450 bp) region in AGS cells. (J) ChIP-qPCR analysis of the impact of orlistat (40 µM) on the binding of FOXM1 to the PD-L1 promoter. (K) The luciferase activity of PD-L1 promoter after FOXM1 overexpression with or without orlistat (40 µM). HEK293T cells in 24-well plates were transfected with FOXM1 plasmids or control. The luciferase activity was measured 36 hours later. *p<0.05, **p<0.01, ***p<0.001.

    Article Snippet: Following activation, STAT1 (TargetMol, TMPJ- 00961) was immobilized on the sensor chip surface using a sodium acetate buffer (pH 5.0).

    Techniques: Inhibition, Expressing, Quantitative RT-PCR, Immunohistochemical staining, Staining, Transfection, Over Expression, Knockdown, ChIP-qPCR, Binding Assay, Luciferase, Activity Assay, Control

    Figure 8 Orlistat upregulates ISGs and MHC-I through activating the STAT1 pathway. (A) Gene set enrichment plots of the antigen processing and presentation hallmarks. (B) Gene set enrichment plots of the JAK-STAT signaling pathway hallmarks. (C–E) WB analysis of Y701-phosphorylated STAT1 (p-STAT1-701) and total STAT1 in AGS and MC38 cells at different times (C) and concentrations (D) after orlistat administration, and tumors collected from mice-bearing subcutaneous MC38 tumors with or without orlistat treatment (E). (F–K) Quantitative PCR analysis of mRNA expression of IFNα, IFNβ, and ISGs or antigen processing and presentation genes in purified MC38 syngeneic tumors cells treated with control or orlistat (F), MC38 (H, I), and AGS (J, K) cell lines. (L) IB analysis and quantitative data of STAT1 in DMSO control vs orlistat-treated cells. AGS cells were treated with cycloheximide (CHX) 100 mg/mL, and collected at the indicated times. (M) Orlistat administration (40 µM) increased the thermal stability of STAT1 protein as determined by thermal stability shift assay (n=3). (N, O) SPR sensorgrams (N) and steady-state curves (O) for the orlistat analyte (2-fold dilutions; 50–1.56 µM) binding to the STAT1 protein ligand. (P) Schematic diagram depicting orlistat-mediated inhibition of PD-L1 expression in gastric cancer and colon cancer cells and promoting the expression of ISGs and MHC-I **p<0.01, ***p<0.001.

    Journal: Journal for immunotherapy of cancer

    Article Title: Orlistat facilitates immunotherapy via AKT-FOXO3a-FOXM1-mediated PD-L1 suppression.

    doi: 10.1136/jitc-2024-008923

    Figure Lengend Snippet: Figure 8 Orlistat upregulates ISGs and MHC-I through activating the STAT1 pathway. (A) Gene set enrichment plots of the antigen processing and presentation hallmarks. (B) Gene set enrichment plots of the JAK-STAT signaling pathway hallmarks. (C–E) WB analysis of Y701-phosphorylated STAT1 (p-STAT1-701) and total STAT1 in AGS and MC38 cells at different times (C) and concentrations (D) after orlistat administration, and tumors collected from mice-bearing subcutaneous MC38 tumors with or without orlistat treatment (E). (F–K) Quantitative PCR analysis of mRNA expression of IFNα, IFNβ, and ISGs or antigen processing and presentation genes in purified MC38 syngeneic tumors cells treated with control or orlistat (F), MC38 (H, I), and AGS (J, K) cell lines. (L) IB analysis and quantitative data of STAT1 in DMSO control vs orlistat-treated cells. AGS cells were treated with cycloheximide (CHX) 100 mg/mL, and collected at the indicated times. (M) Orlistat administration (40 µM) increased the thermal stability of STAT1 protein as determined by thermal stability shift assay (n=3). (N, O) SPR sensorgrams (N) and steady-state curves (O) for the orlistat analyte (2-fold dilutions; 50–1.56 µM) binding to the STAT1 protein ligand. (P) Schematic diagram depicting orlistat-mediated inhibition of PD-L1 expression in gastric cancer and colon cancer cells and promoting the expression of ISGs and MHC-I **p<0.01, ***p<0.001.

    Article Snippet: Following activation, STAT1 (TargetMol, TMPJ- 00961) was immobilized on the sensor chip surface using a sodium acetate buffer (pH 5.0).

    Techniques: Real-time Polymerase Chain Reaction, Expressing, Control, Shift Assay, Binding Assay, Inhibition

    Molecular docking and dynamic simulations of ROF and JAKs/STATs signaling molecules (A) The binding modes of ROF toward JAK2, JAK3, STAT1, and STAT3. (B–F) The dynamic simulations of JAK2-ROF and JAK3-ROF complexes. The HBond (B), RMSD curves (C), RMSF values (D), Rg values (E), and SASA (F) were analyzed by GROMACS.

    Journal: ACS Omega

    Article Title: Rhoifolin Attenuates Concanavalin A-Induced Autoimmune Hepatitis in Mice via JAKs/STATs Mediated Immune and Apoptotic Processes

    doi: 10.1021/acsomega.4c07915

    Figure Lengend Snippet: Molecular docking and dynamic simulations of ROF and JAKs/STATs signaling molecules (A) The binding modes of ROF toward JAK2, JAK3, STAT1, and STAT3. (B–F) The dynamic simulations of JAK2-ROF and JAK3-ROF complexes. The HBond (B), RMSD curves (C), RMSF values (D), Rg values (E), and SASA (F) were analyzed by GROMACS.

    Article Snippet: The antibodies for cleaved-caspase-3, cleaved-caspase-9, Bax, Bcl-2, JAK2, p-JAK2, JAK3, p-JAK3, IL-6, STAT1, p-STAT1, STAT3, p-STAT3, and BNIP3 were diluted at a ratio of 1:1000, and β-actin (#BA2305, BOSTER) was diluted at a ratio of 1:5000 in the primary antibody dilution buffer.

    Techniques: Binding Assay

    Effects of ROF on the JAK2/3-STAT1/3 signaling pathways in Con A-induced hepatitis (A) The phosphorylated levels of JAK2, STAT1, and STAT3 were measured in hepatic tissues using IHC staining ( n = 3; scale bar = 40 μm). (B) The IODs of each protein were detected by using ImageJ. (C) The JAK2/3-STAT1/3 signaling molecules were measured in hepatic tissues with Western blot analysis ( n = 3). The gray value analysis was standardized using the intensity of β-actin and is depicted in bar graphs. The results are presented as mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001 vs the Con A group.

    Journal: ACS Omega

    Article Title: Rhoifolin Attenuates Concanavalin A-Induced Autoimmune Hepatitis in Mice via JAKs/STATs Mediated Immune and Apoptotic Processes

    doi: 10.1021/acsomega.4c07915

    Figure Lengend Snippet: Effects of ROF on the JAK2/3-STAT1/3 signaling pathways in Con A-induced hepatitis (A) The phosphorylated levels of JAK2, STAT1, and STAT3 were measured in hepatic tissues using IHC staining ( n = 3; scale bar = 40 μm). (B) The IODs of each protein were detected by using ImageJ. (C) The JAK2/3-STAT1/3 signaling molecules were measured in hepatic tissues with Western blot analysis ( n = 3). The gray value analysis was standardized using the intensity of β-actin and is depicted in bar graphs. The results are presented as mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001 vs the Con A group.

    Article Snippet: The antibodies for cleaved-caspase-3, cleaved-caspase-9, Bax, Bcl-2, JAK2, p-JAK2, JAK3, p-JAK3, IL-6, STAT1, p-STAT1, STAT3, p-STAT3, and BNIP3 were diluted at a ratio of 1:1000, and β-actin (#BA2305, BOSTER) was diluted at a ratio of 1:5000 in the primary antibody dilution buffer.

    Techniques: Protein-Protein interactions, Immunohistochemistry, Western Blot

    Effects of ROF on Th1/Th17 cells differentiation in vitro (A) The purity of isolated CD4 + T cells was measured by flow cytometry. (B) The viability of CD4 + T cells following 5–20 μM ROF treatments for 24 h was assessed utilizing the CCK-8 assay. (C, D) CD4 + T cells were pre-exposed for 1 h to ROF (20 μM), TOF (1 μM), or ROF (20 μM) + TOF (1 μM), followed by stimulation with Con A for 24 h. The levels of p-JAK2, p-JAK3, p-STAT1, and p-STAT3 were monitored by Western blotting and normalized to each protein’s total concentration in the graphs. (E) The generation of IFN-γ or IL-17 in the cellular supernatants of Th1 or Th17 subtypes were measured using ELISA. (F) The gene expression levels of T-bet or RORγt in differentiated T cells were evaluated by PCR. The values are presented as mean ± SEM ( n = 3). ** P < 0.01, *** P < 0.001 vs the Con A group. # P < 0.05, ## P < 0.01, ### P < 0.001 vs the ROF only group or TOF only group.

    Journal: ACS Omega

    Article Title: Rhoifolin Attenuates Concanavalin A-Induced Autoimmune Hepatitis in Mice via JAKs/STATs Mediated Immune and Apoptotic Processes

    doi: 10.1021/acsomega.4c07915

    Figure Lengend Snippet: Effects of ROF on Th1/Th17 cells differentiation in vitro (A) The purity of isolated CD4 + T cells was measured by flow cytometry. (B) The viability of CD4 + T cells following 5–20 μM ROF treatments for 24 h was assessed utilizing the CCK-8 assay. (C, D) CD4 + T cells were pre-exposed for 1 h to ROF (20 μM), TOF (1 μM), or ROF (20 μM) + TOF (1 μM), followed by stimulation with Con A for 24 h. The levels of p-JAK2, p-JAK3, p-STAT1, and p-STAT3 were monitored by Western blotting and normalized to each protein’s total concentration in the graphs. (E) The generation of IFN-γ or IL-17 in the cellular supernatants of Th1 or Th17 subtypes were measured using ELISA. (F) The gene expression levels of T-bet or RORγt in differentiated T cells were evaluated by PCR. The values are presented as mean ± SEM ( n = 3). ** P < 0.01, *** P < 0.001 vs the Con A group. # P < 0.05, ## P < 0.01, ### P < 0.001 vs the ROF only group or TOF only group.

    Article Snippet: The antibodies for cleaved-caspase-3, cleaved-caspase-9, Bax, Bcl-2, JAK2, p-JAK2, JAK3, p-JAK3, IL-6, STAT1, p-STAT1, STAT3, p-STAT3, and BNIP3 were diluted at a ratio of 1:1000, and β-actin (#BA2305, BOSTER) was diluted at a ratio of 1:5000 in the primary antibody dilution buffer.

    Techniques: In Vitro, Isolation, Flow Cytometry, CCK-8 Assay, Western Blot, Concentration Assay, Enzyme-linked Immunosorbent Assay, Gene Expression

    Effects of ROF on primary hepatocytes apoptosis in vitro (A) Primary hepatocytes were pretreated with ROF (5, 10, 20 μM) for 6 h and treated with or without Con A (10 μg/mL) for 24 h, the cell viability of each group was analyzed by CCK-8 assay. (B) Flow cytometry analysis of apoptosis in primary hepatocytes. (C) Primary hepatocytes were pretreated with ROF (20 μM), TOF (1 μM), or ROF (20 μM) + TOF (1 μM) for 6 h, and subsequently triggered with Con A (10 μg/mL) for 24 h. The IL-6, p-JAK2, p-STAT1, p-STAT3, BNIP3, and Bax expression levels were evaluated by using Western blotting. (D) The quantification and standardization of the protein expression were performed using ImageJ. The results are presented as mean ± SEM of three independent experiments. ** P < 0.01, *** P < 0.001 vs the Con A group. # P < 0.05, ## P < 0.01 vs the ROF only group or TOF only group.

    Journal: ACS Omega

    Article Title: Rhoifolin Attenuates Concanavalin A-Induced Autoimmune Hepatitis in Mice via JAKs/STATs Mediated Immune and Apoptotic Processes

    doi: 10.1021/acsomega.4c07915

    Figure Lengend Snippet: Effects of ROF on primary hepatocytes apoptosis in vitro (A) Primary hepatocytes were pretreated with ROF (5, 10, 20 μM) for 6 h and treated with or without Con A (10 μg/mL) for 24 h, the cell viability of each group was analyzed by CCK-8 assay. (B) Flow cytometry analysis of apoptosis in primary hepatocytes. (C) Primary hepatocytes were pretreated with ROF (20 μM), TOF (1 μM), or ROF (20 μM) + TOF (1 μM) for 6 h, and subsequently triggered with Con A (10 μg/mL) for 24 h. The IL-6, p-JAK2, p-STAT1, p-STAT3, BNIP3, and Bax expression levels were evaluated by using Western blotting. (D) The quantification and standardization of the protein expression were performed using ImageJ. The results are presented as mean ± SEM of three independent experiments. ** P < 0.01, *** P < 0.001 vs the Con A group. # P < 0.05, ## P < 0.01 vs the ROF only group or TOF only group.

    Article Snippet: The antibodies for cleaved-caspase-3, cleaved-caspase-9, Bax, Bcl-2, JAK2, p-JAK2, JAK3, p-JAK3, IL-6, STAT1, p-STAT1, STAT3, p-STAT3, and BNIP3 were diluted at a ratio of 1:1000, and β-actin (#BA2305, BOSTER) was diluted at a ratio of 1:5000 in the primary antibody dilution buffer.

    Techniques: In Vitro, CCK-8 Assay, Flow Cytometry, Expressing, Western Blot